Metsera, Inc. Common Stock (MTSR) Stock Analysis

Metsera, Inc. Common Stock (MTSR) is a publicly traded company in the HEALTHCARE sector. It trades at $70.50. This page summarizes the public market data, fundamentals, and frequently asked questions for MTSR, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $70.50

Market Sentiment

Metsera, Inc. Common Stock currently has a Neutral sentiment score of 0.04.

About Metsera, Inc. Common Stock

Metsera, Inc. is a clinical-stage biotechnology company headquartered in New York, dedicated to the development of innovative injectable and oral hormone analog peptides targeting obesity and related metabolic disorders. By harnessing advanced peptide technology, Metsera aims to revolutionize obesity management with its novel therapeutic solutions. The company's robust pipeline and commitment to scientific innovation signal significant growth potential in the health and wellness sector, posit...

GNG Research Analysis

GNG Research scores Metsera, Inc. Common Stock (MTSR) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for MTSR.

Frequently Asked Questions

Does MTSR pay dividends?

Metsera, Inc. Common Stock (MTSR) does not currently pay a regular dividend.